Kymriah

{
  "id": "MLC-T-ONC-004676",
  "term": "Kymriah",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with certain types of B-cell non-Hodgkin lymphoma and people up to 25 years old with certain types of B-cell acute lymphoblastic leukemia. It is also being studied in the treatment of other types of cancer. Kymriah is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Kymriah binds to a protein called CD19, which is found on some leukemia and lymphoma cells. This helps the body’s immune system kill cancer cells. Kymriah is a type of CAR T-cell therapy. Also called tisagenlecleucel.",
  "synonyms": [
    "tisagenlecleucel"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/kymriah/"
}